



## Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021

August 10, 2021

CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 10, 2021-- [Lineage Cell Therapeutics, Inc.](#) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company's Chief Executive Officer, will be participating in and presenting at the [H.C. Wainwright & Co. Inc. Virtual Ophthalmology Conference](#). Mr. Culley's presentation will be available on-demand starting on August 17<sup>th</sup>, 2021 at 7am ET / 4am PT. Mr. Culley will also participate in an industry panel, *Addressing Unmet Medical Needs in Macular Degeneration – Dry AMD and Stargardt Disease*, hosted by Yi Chen, Ph.D., CFA, Managing Director, Senior Healthcare Analyst, H.C. Wainwright & Co., Inc., on August 17<sup>th</sup>, 2021 at 11am ET / 8am PT.

Interested parties can register to view both the on-demand and live industry panel presentations on the [Events and Presentations](#) section of Lineage's website. Additional videos are available on the [Media](#) page of the Lineage website.

### About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage's clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen<sup>®</sup>, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of subacute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit [www.lineagecell.com](http://www.lineagecell.com) or follow the Company on Twitter [@LineageCell](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210810005334/en/): <https://www.businesswire.com/news/home/20210810005334/en/>

### Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone  
([ir@lineagecell.com](mailto:ir@lineagecell.com))  
(442) 287-8963

### Solebury Trout IR

Gitanjali Jain Ogawa  
([Gogawa@soleburytrout.com](mailto:Gogawa@soleburytrout.com))  
(646) 378-2949

### Russo Partners – Media Relations

Nic Johnson or David Schull  
([Nic.johnson@russopartnersllc.com](mailto:Nic.johnson@russopartnersllc.com))  
([David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com))  
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.